accessibility menu, dialog, popup

UserName
Viewing profile as user:

Lactams

Organic heterocyclic compounds that contain a cyclic amide; amide groups consist of a carbonyl carbon atom linked by a single bond to a nitrogen atom and either a hydrogen or a carbon atom. These compounds are the nitrogen analogs of lactones.

Filtered Search Results

Products from some of our suppliers do not display in filtered search results. Please clear all filters to see these products.

Narrow Results

Narrow Results

category

brands

  • (3)

special interests

  • (3)

Search Within Results
Keyword Search:
1 – 3 of 3 results
1

Medchemexpress LLC N-[2-amino-5-(2-thienyl)phenyl]-2-(1-piperazinyl)-6-quinolinecarboxamide | 1609389-52-7 | 99.6% | 429.54 g/mol | C24H23N5OS | 100 MG
SDP

ACY-957 is a small-molecule, orally active inhibitor selective for histone deacetylases HDAC1 and HDAC2, used in preclinical research to modulate epigenetic regulation and induce γ-globin expression. CAS 1609389-52-7; formula C24H23N5OS; molecular weight 429.54 g/mol.

  • Selective inhibition of HDAC1 and HDAC2 (IC50 7 nM and 18 nM)
  • Markedly reduced activity against HDAC3 (IC50 ≈ 1,300 nM), supporting class I selectivity
  • Orally active in preclinical models, suitable for in vivo dosing studies
  • High reported purity for research-grade material (~99.6%)
  • Solid, light yellow to yellow form; stable when stored at -20 °C
  • Used to study epigenetic regulation and hemoglobin induction in preclinical research

ENCOMPASS_PREFERRED
2

Medchemexpress LLC N-[2-amino-5-(2-thienyl)phenyl]-2-(1-piperazinyl)-6-quinolinecarboxamide | 1609389-52-7 | 99.6% | 429.54 g/mol | C24H23N5OS | 1 ML
SDP

ACY-957 is an orally active, selective small-molecule inhibitor of histone deacetylases HDAC1 and HDAC2 used in preclinical research to modulate epigenetic regulation and induce fetal hemoglobin expression. Reported IC50 values are 7 nM (HDAC1), 18 nM (HDAC2), and 1,300 nM (HDAC3). Supplied for in vitro and in vivo studies.

  • Selective inhibition of HDAC1 and HDAC2 with low-nanomolar potency.
  • Demonstrated activity in cellular models of globin gene induction.
  • Orally active in preclinical pharmacology studies.
  • Suitable for both in vitro and in vivo research applications.
  • Characterized with vendor-provided purity and analytical data.

ENCOMPASS_PREFERRED
3

Medchemexpress LLC N-(2-amino-5-(thiophen-2-yl)phenyl)-2-(piperazin-1-yl)quinoline-6-carboxamide | 1609389-52-7 | MFCD30342405 | 99.6% | 429.54 g·mol⁻¹ | C24H23N5OS | 25 MG
SDP

ACY-957 is a small-molecule, orally active inhibitor selective for histone deacetylases HDAC1 and HDAC2 used in preclinical research. It potently inhibits HDAC1 (IC50 = 7 nM) and HDAC2 (IC50 = 18 nM), with substantially weaker activity against HDAC3 (IC50 = 1,300 nM), and shows no significant inhibition of HDAC4-HDAC9. The compound is provided as a purified research reagent for biochemical and cellular studies of epigenetic regulation.

  • Potent HDAC1 inhibition (IC50 = 7 nM).
  • Selective for HDAC1/2 over HDAC3 (IC50 HDAC2 = 18 nM; HDAC3 = 1,300 nM).
  • Orally active profile reported in preclinical studies.
  • Suitable for biochemical and cellular assays investigating epigenetic regulation.
  • High chemical purity for reproducible experimental results.

ENCOMPASS_PREFERRED